A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Inclusion Criteria: * Histologically confirmed MCL * Has received one prior regimen for MCL * Disease is relapsed or refractory * At least 1 measurable site of disease that is ≥ 2.0 cm * PET-CT performed less than 28 days before study entry * If a subject has toxicities due to prior therapy for the treatment of MCL, must be stable and recovered * Eastern Cooperative Oncology Group performance status of 0 or 1. * Study-specific laboratory parameters must be met * Females of childbearing potential and males must use highly effective contraception Exclusion Criteria: * Received more than one month of prior therapy with ibrutinib or any other Bruton's tyrosine kinase inhibitor * Concurrent enrollment in another investigational study * Transfusion-dependent thrombocytopenia * Anticancer therapy within 25 days before the start of the study * History of other malignancy, cancer, or carcinoma for at least three years before the start of the study * Central nervous system (CNS) involvement with lymphoma * CNS disorder ≤ 6 months of study entry * History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, active arrhythmias, class 3 or 4 congestive heart failure, or other clinically significant cardiac disease ≤ 6 months of study entry * Active or prior cardiac (atrial or ventricular) lymphoma involvement * History of atrial fibrillation or left or right bundle branch block * History of symptomatic deep vein thrombosis or pulmonary embolism ≤ 6 months of study entry * Chronic liver disease with hepatic impairment, Child-Pugh class B or C * Bleeding disorder * Prior stem cell transplant that requires ongoing immunosuppressive therapy or active clinical graft versus host disease * Primary severe immunodeficiency * Human immunodeficiency virus infection (HIV) or active hepatitis B or C infection * Active infection requiring IV antimicrobial (antiviral, antibiotic, anti-fungal) therapy at the time of study entry * Vaccination with a live, attenuated vaccine ≤ 4 weeks of the start of the study * Hypersensitivity reaction to any of the agents used in this study * Requires treatment with a strong cytochrome P450 enzyme (CYP) 3A (CYP3A) inhibitor/inducer. * Unable or swallow capsules or tablets or has malabsorption syndrome or disease affecting gastrointestinal function * Major surgery ≤ 4 weeks of study start * Medical condition likely to interfere with assessment of safety or efficacy of the study drug * Not eligible in the opinion of the Investigator * Pregnant or breastfeeding Other protocol-defined inclusion/exclusion criteria will apply.